Dobrina Tsvetkova, Stefka Ivano

Abstract

The aim of the current study was the investigation of HPLC behaviour, separation and system suitability for the combination of Galantamine hydrobromide/Pymadine in model mixtures, in accordance with the new trend of multi-target therapy of Alzheimer’s disease by combining acetylcholinesterase inhibitor with its potential synergist. The system suitability test for the simultaneous determination of the components was carried out by the following criteria: 1) retention times in the analysis of 6 model mixtures; 2) the change of values for separation degrees in minor changes of the ratio of mobile phase components and mobile phase flow rates. The system suitability was confirmed by the lack of the statistically significant differences between the values of parameter retention time  t_R [min.]: t_R = 3.179 (Galantamine hydrobromide), t_R = 5.272 (Pymadine). In changing the ratio of mobile phase components, the data for separation degree were in the range of 1.76 ÷ 1.83, and the symmetry factor (T) was in the range of 0.94 ÷ 1 (Galantamine hydrobromide), 0.96 ÷ 1.03 (Pymadine). Upon varying the mobile phase velocity, T values varied between 0.94 ÷ 1 (Galantamine hydrobromide) and 0.95 ÷ 1.06 (Pymadine). The system suitability was confirmed by the fact that minor changes in the ratio of the mobile phase components or in the mobile phase flow rate didn’t decrease the degree of separation.